Thrombotic Outcomes from rEPO or Darbopoietin Use in Cancer Patients Bohlius: The Cochrane Library, Volume (4).2006 Among 6,769 pts with cancer, RR for DVT with rEPO/Darbepo was increased by 67% (RR=1.67; 95% CI 1.35 to 2.06)
{}